sitagliptin

sitagliptin. It is a medication used for the treatment of type 2 diabetes mellitus and belongs to the dipeptidyl peptidase-4 inhibitor class of drugs. Marketed by Merck & Co. under the brand name Januvia, it works by increasing levels of incretin hormones, which help control blood glucose. It is often prescribed when metformin and lifestyle changes are insufficient for glycemic control.

Medical uses

sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy or in combination with other antihyperglycemic agents, such as metformin, a sulfonylurea, a thiazolidinedione, or insulin. Clinical trials, including those reviewed by the U.S. Food and Drug Administration, have demonstrated its efficacy in lowering hemoglobin A1c levels. It is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

Adverse effects

Common adverse reactions include nasopharyngitis, headache, and upper respiratory tract infection. More serious but rare risks include severe joint pain, acute pancreatitis, and hypersensitivity reactions such as angioedema. Post-marketing surveillance has reported cases of bullous pemphigoid and a potential increased risk of heart failure, though large studies like TECOS did not show a significant increase in major cardiovascular events. The European Medicines Agency and other regulatory bodies continue to monitor its safety profile.

Pharmacology

sitagliptin functions as a selective, competitive inhibitor of the enzyme dipeptidyl peptidase-4. This inhibition increases the concentration and activity of endogenous incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. These hormones stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner and suppress glucagon release from pancreatic alpha cells. It is rapidly absorbed after oral administration, with peak plasma concentrations occurring in one to four hours, and is primarily excreted unchanged in the urine via renal tubular secretion.

History

The development of sitagliptin originated from research on dipeptidyl peptidase-4 as a therapeutic target for diabetes at Merck Research Laboratories. Its discovery and optimization were led by scientists including Ann E. Weber. Following successful Phase III clinical trials, it received approval from the U.S. Food and Drug Administration in October 2006, becoming the first DPP-4 inhibitor marketed in the United States. Subsequent approvals followed from the European Commission and other agencies worldwide, establishing it as a major product for Merck & Co..

Society and culture

sitagliptin is available under the brand name Januvia and in fixed-dose combinations with metformin as Janumet and with metformin hydrochloride extended-release as Janumet XR. It has been a subject of formulary discussions within organizations like the National Institute for Health and Care Excellence and the American Diabetes Association. The drug has been featured in prominent clinical guidelines and was a central therapy in the TECOS cardiovascular outcomes trial. Its patent expiration has influenced the market for antidiabetic medications.

Category:Antidiabetic drugs Category:Dipeptidyl peptidase-4 inhibitors Category:Merck & Co. brands